胰腺癌患者血浆miR-155检测及其诊断价值

目的 检测胰腺癌患者血浆miR-155表达量,评价其对胰腺癌的诊断价值.方法 收集62例胰腺癌、61例慢性胰腺炎(CP)及36例正常对照者的血标本,抽提血浆RNA,应用实时PCR检测miR-155表达量,并分析其与胰腺癌临床参数的关系.应用接受者操作特征(ROC)曲线下面积(AUC)评价血浆miR-155表达量对胰腺癌的诊断价值.结果 胰腺癌、CP和正常对照组的血浆miR-155表达量分别为5.41±3.14、2.59±2.49和0.77±1.17,胰腺癌血浆miR-155表达量显著高于CP及正常对照组(P＜0.01).胰腺癌血浆miR-155表达量与患者年龄、性别、肿瘤大小等均无显著相关性,而与肿瘤TNM分期呈显著负相关(r=-0.323,P=0.01).经ROC分析,胰腺癌对正常对照组的AUC为0.943(95%CI0.902～0.985),敏感性和特异性分别为87.1%和83.3%;胰腺癌对CP的AUC为0.762(95%CI0.678～0.846),敏感性和特异性分别为64.5%和73.8%;胰腺癌对正常对照组+CP组的AUC为0.829(95%CI0.767～0.892),敏感性和特异性分别为62.9%和84.5%.结论 胰腺癌患者血浆miR-155表达量显著升高,对胰腺癌的诊断可能有一定的应用价值.

Diagnostic value of plasma miR 55 for pancreatic cancer

Objective To detect the level of plasma miR-155 in patients with pancreatic cancer and evaluate its diagnostic value for pancreatic cancer. Methods Sixty-two cases of pancreatic cancer patients, 61 patients of chronic pancreatitis and 36 normal controls were included in the study. miR-155 in the total RNA extracted from the plasma was measured using real time PCR. The diagnostic parameters and relationship of the miR-155 with clinical characteristics in pancreatic cancer patients were analyzed. Results The relative abundance of plasma miR-155 in pancreatic cancer, chronic pancreatitis and normal controls were 5.41 ±3.14,2.59 ±2.49 and 0.77 ± 1.17, and the value was significantly higher in pancreatic cancer group compared with those of chronic pancreatitis and normal group (P ＜ 0. 01 ). No significant correlation between the level of plasma miR-155 and age, sex, tumor size in pancreatic cancer patients was found. But there was a negative correlation between the level of plasma miR-155 and TNM staging (r = -0. 323, P = 0.01 ). For discriminating pancreatic cancer from normal control, the AUC ROC of miR-155 was 0. 943 (95% CI 0.902-0.985), and the sensitivity and specificity were 87.1% and 83.3%, respectively. For discriminating pancreatic cancer from chronic pancreatitis, the AUC ROC of miR-155 was 0.762 (95% CI0. 678-0. 846),and the sensitivity and specificity were 64.5% and 73.8%, respectively. For discriminating pancreatic cancer from chronic pancreatitis and normal, the AUC-ROC of miR-155 was 0. 829(95% CI0. 767-0.892), and the sensitivity and specificity were 62.9% and 84.5%, respectively. Conclusions Plasma miR-155 was significantly increased in patients with pancreatic cancer, and can be used for diagnosis of pancreatic cancer.